Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5-Reference-Cited by-同舟云学术

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5

Published:2022-08 Issue:8 Volume:22 Page:1117-1118
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Arora Prerna,Kempf Amy,Nehlmeier Inga,Schulz Sebastian R,Cossmann Anne,Stankov Metodi V,Jäck Hans-Martin,Behrens Georg M N,Pöhlmann Stefan,Hoffmann Markus

Funder

Deutsches Zentrum fur Infektionsforschung eV

Bavarian State Ministry of Science Research and Art

Niedersachsisches Ministerium fur Wissenschaft und Kultur

Deutsche Forschungsgemeinschaft

Bundesministerium für Bildung und Forschung

Bayerische Forschungsstiftung

Bundesministerium für Bildung und Forschung Dienststelle Berlin

European Regional Development Fund

Niedersächsisches Ministerium für Wissenschaft und Kultur

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference8 articles.

1. The omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic;Hoffmann;Cell,2022

2. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses;Schmidt;J Exp Med,2020

3. Broadly neutralizing antibodies overcome SARS-CoV-2 omicron antigenic shift;Cameroni;Nature,2022

4. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by omicron infection (version 2);Cao;bioRxiv,2022

5. Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies;Yamasoba;Lancet Infect Dis,2022

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity and safety of a recombinant Omicron BA.4/5-Delta COVID-19 vaccine ZF2202-A in Chinese adults;Vaccine;2024-05

2. SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs;Cell Chemical Biology;2024-04

3. A VHH single-domain platform enabling discovery and development of monospecific antibodies and modular neutralizing bispecifics against SARS-CoV-2 variants;Antibody Therapeutics;2024-03-28

4. A computational method for anti-SARS-CoV-2 antibodies neutralization power: A blueprint with monoclonal antibody Sotrovimab (Preprint);JMIR Bioinformatics and Biotechnology;2024-03-04

5. A computational method for anti-SARS-CoV-2 antibodies neutralization power: A blueprint with monoclonal antibody Sotrovimab (Preprint);2024-03-04